Navigation Links
NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
Date:12/17/2008

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid and p<0.05 for naproxcinod 375 mg bid). Naproxcinod is the first compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

A significantly lower proportion of patients on naproxcinod experienced an increase in SBP of 5 mmHg or more, compared to naproxen

Over the whole 13 week period the proportion of patients whose SBP increased by 5 mmHg or more was higher for naproxen 500 mg bid, as compared to naproxcinod 750 mg bid (p<0.001), naproxcinod 375 mg bid (p=0.013) and placebo (p<0.001).

Both naproxcinod doses showed a similar blood pressure profile to placebo, in contrast to naproxen which raised SBP (p<0.001)

There is a clear unmet medical need for a novel anti-inflammatory agent with no detrimental impact on blood pressure. COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, are widely used for the symptomatic treatment of OA but can lead to the onset of new episodes of high blood pressure or worsening of pre-existing hypertension. Both doses of naproxcinod (375 and 750 mg bid) were similar to placebo, as indicated by one-sided 95% confidence intervals (CIs). In contrast, naproxen 500 mg bid raised SBP compared to placebo (p<0.001).

Garret FitzGerald, MD, Professor of Medicine and Pharmacology at the University of Pennsylvania School of Medicine, commented:
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1379

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
2. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
3. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
4. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
5. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
6. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
11. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Revenue and earnings ... on research and development In the past 2013/14 ... by two percent to EUR 4.287 billion (last year: EUR ... 14 percent to EUR 360 million. "Overall, 2013/14 was a ... Michael Kaschke , President and CEO of Carl Zeiss AG. ...
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, ... US Patent and Trademark Office (USPTO) has issued ... a dendritic cell-based immunotherapeutic vaccine targeting six tumor ... claims of US Patent No. 8,871,211, which issued ... cancer by administering a dendritic cell composition comprising ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
(Date:12/21/2014)... York, NY (PRWEB) December 21, 2014 ... nearing 1,400 in a consolidated litigation underway in New ... documents, a total of 1,375 claims involving the birth ... Superior Court. These lawsuits were filed by women who ... to have led to uterine perforations and other complications ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas ... time helping people get their health back. Mission for ... serving those persons in Muskegon County who are unable to ... of life. Dr. Michael Rykse wanted to do a Toy ... and he knew he found that when he heard what ...
(Date:12/21/2014)... San Francisco, California (PRWEB) December 21, 2014 ... announces his search for Vintage 1967 Jm Morrison and the ... D.C. concert posters. This would also be the only ... live. The concert was on Nov. 25, 1967. According ... in Washington D.C. They did play the Alexandria Roller ...
(Date:12/21/2014)... 21, 2014 Parker & Sons, Inc. ... cooling, plumbing and other similar home contractor services announces ... regard to its expert contracting services. The company is ... has been serving Arizona for well over 40 years. ... absolute best in quality customer service to the residents ...
(Date:12/21/2014)... December 21, 2014 Over the past ... issues in hundreds of emergency departments across the nation, ... findings have been translated into an innovative suite of ... correct deficiencies and enhance the patient experience. , ... physician staffing and management services for hospitals, announced the ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... has been selected for the Physician of the Year Award by ... surgeon director in Otolaryngology at the same Infirmary, will be presented ... Nov 20 in New York., ,Mehta graduated in medicine from ... He has been affiliated with the Infirmary for more than 25 ...
... 50 percent of the clan is found battling chronic skin ... new study has claimed that nearly 50,000 hair stylists are ... shampoos that render constantly moist hands., ,Due to this, ... on with their jobs when the condition worsens. Hairdressers are ...
... more salt than the deep blue sea, according to a ... brings about a dramatic reduction in their blood pressure which ... disease and stroke later in life. ,The report states ... Twirls contain more than twice as much salt as the ...
... that although very difficult to disseminate actual figures it ... of the funds allocated for the disbursement of medicines ... or lost because of fraudulent practices, bribery and diversion ... assessed that governments spent about US$50 billion (€39 billion) ...
... killer H5N1 avian flu virus that had emerged in early ... resistant to the vaccination programme and might even be aided ... wave of transmission of H5N1 avian flu and could potentially ... of the Proceedings of National Academy of Sciences. ,The ...
... regularly, because the size of your paunch is directly related ... new research conducted by a medical expert of Indian origin. ... University of Leicester, obesity has now become a worldwide epidemic. ... currently over half of women and two-thirds of men in ...
Cached Medicine News:Health News:Hair-raising issues of hairdressers 2Health News:Kids' Food: Saltier than the Deep Blue Sea 2Health News:Kids' Food: Saltier than the Deep Blue Sea 3Health News:Kids' Food: Saltier than the Deep Blue Sea 4
... dimeglumine) is a paramagnetic MRI contrast agent. ... gadobenate, a chelating agent that forms a ... ion. It is salified with meglumine forming ... all the physico-chemical features typical of gadolinium ...
... OMNISCAN was launched in the U.S. ... the central nervous system (CNS) to detect ... associated tissues. OMNISCAN has since received approval ... and pediatric CNS and body indications. OMNISCAN ...
... dimeglumine) injection was introduced in 1988, it ... magnetic resonance imaging (MRI). It became the ... MRI. Today, the product is still a ... neck and body. MAGNEVIST is used in ...
... in 1996, VISIPAQUE is the only isosmolar contrast ... osmolality equal to that of blood, VISIPAQUE was ... also the only contrast medium formulated with sodium ... In 1997, VISIPAQUE received FDA approval for use ...
Medicine Products: